2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2016 Featured Talks » The bone niche and therapy resistance in bone metastatic prostate cancer

Christina Jamieson, Part 1 from MCC Industry Relations on Vimeo.

Christina Jamieson, part 2 from MCC Industry Relations on Vimeo.

Christina Jamieson, PhD
Associate Professor of Surgery and Urology
UC San Diego Moores Cancer Center

Christina Jamieson received a BSc, Honors, from the University of British Columbia (UBC), Vancouver, BC, Canada, and PhD in Molecular Immunology with Dr. Ranjan Sen, Brandeis University, Waltham, MA and showed for the first time that the T cell receptor (TCR) actives NF-kB. Dr. Jamieson did post-doctoral training at the University of California, San Francisco (UCSF) with Dr. Dan R Littman then Dr. Keith R. Yamamoto and showed that TCR signaling crosstalk alters the transcriptional function and output of the steroid hormone receptor, GR, thus inhibiting apoptosis. Using a functional genomics approach she studied signaling crosstalk of TCR and GR as a potential mechanism of therapy resistance in cancer. Dr. Jamieson joined the University of California at Los Angeles as an Assistant Professor in the Departments of Urology and Human Genetics, where she initiated her work on bone metastatic prostate cancer and resistance to androgen receptor (AR) targeted therapy. Dr. Jamieson moved to the University of California, San Diego, to join the Department of Surgery and Urology where she established new patient-derived xenograft (PDX) models of bone metastatic prostate cancer and a biorepository of surgical prostate cancer bone metastasis specimens. Dr. Jamieson is the first to show that the bone niche is sufficient to support castration resistant growth of prostate cancer. She identified gene networks associated with prostate cancer growth in the bone niche and established co-culture model systems demonstrating that bone marrow stromal cells supported castrate resistant growth of PDX prostate cancer cells. These findings support the hypothesis that signaling crosstalk within the bone niche leads to therapy-resistant growth of cancers. Dr. Jamieson is using new patient-derived xenografts of bone metastatic prostate cancer to develop molecularly targeted therapies and immunotherapies.